The truncated chromosome 22 that results from the reciprocal translocation t (9; 22)(q34;
q11) is known as the Philadelphia chromosome (Ph) and is a hallmark of chronic myeloid …

Chronic myeloid leukemia (CML) is probably the most extensively studied human
malignancy. The discovery of the Philadelphia (Ph) chromosome in 19601 as the first …

In the past decade clinical and laboratory studies have led to important new insights into the
biology of chronic myeloid leukemia (CML). Basic science has defined the molecular …

Imatinib, a potent inhibitor of the oncogenic tyrosine kinase BCR–ABL, has shown
remarkable clinical activity in patients with chronic myelogenous leukaemia (CML) …

This review discusses the development and uses of imatinib mesylate, a protein tyrosine
kinase inhibitor useful in the treatment of chronic myelogenous leukemia and …

Chronic myelogenous leukemia (CML) evolves from a chronic phase characterized by the
Philadelphia chromosome as the sole genetic abnormality into blast crisis, which is often …

The number of genetic lesions necessary to generate leukemia in humans is unknown, but it
is possible that certain specific abnormalities, eg, fusion genes, known to be associated with …

Polymorphonuclear leukocytes are essential for host defense to infectious diseases.
CCAAT/enhancer binding protein ɛ (C/EBPɛ) is preferentially expressed in granulocytes …

Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome–
positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven …

Bcr–Abl is a chimeric oncoprotein that is strongly implicated in acute lymphoblastic (ALL)
and chronic myelogenous leukemias (CML). This deregulated tyrosine kinase selectively …